Skip to main content

Table 1 HCT116 spheroid growth over time in mean and SD. n ≥ 4

From: Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2

 

Untreated

100 kBq 177Lu-rituximab

PM2 [20 μM]

30 kBq 177Lu-AbN44v6

100 kBq 177Lu-AbN44v6

30 kBq 177Lu- AbN44v6 and PM2

100 kBq 177Lu-AbN44v6 and PM2

Day

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

3

2.79

0.14

2.34

0.1

1.56

0.11

2.56

0.13

2.14

0.16

1.47

0.04

1.56

0.01

6

6.44

0.43

4.47

0.21

2.61

0.19

5.15

0.32

3.42

0.32

2.18

0.22

1.92

0.15

10

12.64

1.14

7.81

0.09

5.87

0.74

9.06

0.75

5.1

0.69

4.23

0.68

2.43

0.16

14

21.72

2.17

13.04

1.48

13.5

1.88

13.27

1.22

8

1.53

9.43

1.82

4.15

0.66